Aspira Women’s Health Inc. (NASDAQ:AWH – Get Rating) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 4,900,000 shares, a decrease of 34.2% from the March 15th total of 7,450,000 shares. Approximately 8.6% of the company’s shares are short sold. Based on an average daily volume of 567,300 shares, the days-to-cover ratio is currently 8.6 days.
NASDAQ AWH opened at $1.02 on Friday. The stock has a 50-day simple moving average of $1.05 and a 200 day simple moving average of $1.80. The company has a market capitalization of $114.38 million, a PE ratio of -3.64 and a beta of 2.78. The company has a current ratio of 5.10, a quick ratio of 5.08 and a debt-to-equity ratio of 0.09. Aspira Women’s Health has a 12 month low of $0.87 and a 12 month high of $6.45.
Aspira Women’s Health (NASDAQ:AWH – Get Rating) last posted its earnings results on Wednesday, March 23rd. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). Aspira Women’s Health had a negative return on equity of 75.46% and a negative net margin of 464.80%. During the same period in the previous year, the business earned ($0.58) earnings per share. As a group, sell-side analysts predict that Aspira Women’s Health will post -0.28 earnings per share for the current fiscal year.
A number of equities research analysts recently commented on AWH shares. Zacks Investment Research upgraded Aspira Women’s Health from a “sell” rating to a “hold” rating in a report on Monday, March 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aspira Women’s Health in a report on Tuesday, January 11th.
About Aspira Women’s Health (Get Rating)
Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer.
- Get a free copy of the StockNews.com research report on Aspira Women’s Health (AWH)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.